文献リスト

1) Redman CW, Sargent LL. Latest advances in understanding preeclampsia. Science. 2005; 308: 1592-4

2) Wallukat G, Homuthi V, Luft FC, et al. Patients with preeclampsia develop agonistic auto­anti­bodies against the angiotensin AT1 receptor. J Clin Invest. 1999; 103: 945-52

3) Shah DM. Role of the rennin-angiotensin system in the pathogenesis of preeclampsia. Am J Physiol Renal Physiol. 2005; 288: 614-25

4) Herse F, Dechend R, Staff AC, et al. Dysregulation of the circulating and tissue-based renin-angio­tensin system in preeclampsia. Hypertension. 2007; 49: 604-11

5) Walther T, Wallukat G, Stepan H, et al. Angio­tensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the utero­placental vasculature. Hypertension. 2005; 46: 1275-9

6) Hubel CA, Wallukat G, Dechend R, et al. Ago­nistic angiotensin II type 1 receptor autoanti­bodies in postpartum women with a history of preeclampsia. Hypertension. 2007; 49: 612-7

7) Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365: 785-99

8) Stepan H, Wallukat G, Walther T, et al. Is parvo­virus B19 the cause for autoimmunity against the angiotensin II type receptor？ J Reprod Immunol. 2007; 73: 130-4

9) Herse F, Verlohren S, Dechend R, et al. Pre­valence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009; 53: 393-8

10) Dechend R, Gratze P, Vercruysee L, et al. Agonis­tic autoantibodies to the AT1 receptor in trans­genic rat model of preeclampsia. Hypertension. 2005; 45: 742-6

11) LaMarca B, Wallukat G, Granger JP, et al. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor in pregnant rats. Hypertension. 2008; 52: 1168-72

12) Xia Y, Ramin S, Kelles RE. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension. 2007; 50: 269-75

13) Stepan H, Faber R, Walther T, et al. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of pre­eclampsia. J Clin Endocrinol Metab. 2006; 91: 2424-7

14) Xia Y, Wen H, Kellems RE, et al. Maternal autoantibodies from preeclamptic patients acti­vate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig. 2003; 10: 82-93

15) Xia Y, Wen HY, Kellems RE, et al. Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation. J Biol Chem. 2002; 277: 24601-8

16) Bobst SM, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients acti­vate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens. 2005; 18: 330-6

17) Maynard WE, Min JY, Karamanchi SA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dys­function, hypertension, and proteinnusia in preeclampsia. J Clin Invest. 2003; 111: 649-58

18) Maynard S, Min JY, Karumanchi A, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hyper­tension, and proteinuria inpreeclampsia. J Clin Invest. 2003; 111: 649-58

19) Zhou CC, Ahmad S, Xia Y, et al. Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res. 2007; 100: 88-95

20) Zhou CC, Ahmad S, Day M-C, et al. Autoantibody from women with preeclampsia induces soluble fms-like tyrosine kinase-1 production via angio­tensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension. 2008; 51: 1010-9

21) Dechend R, Viedt C, Luft FC, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation. 2003; 107: 1632-9

22) Thway TM, Shlykob SG, Kellems RE, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2＋ mobilization through angiotensin receptor activation. Circulation. 2004; 110: 1612-9

23) Dechend R, Homuth V, Luft FC, et al. AT1 receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000; 101: 2382-7

24) Dorffel Y, Wallukat G, Scholze J, et al. Agonistic AT1 receptor autoantibodies and monocyte stimulation in hypertensive patients. Am J Hypertens. 2003; 16: 827-33

25) Fu ML, Herlitz H, Hoebeke J, et al. Autoanti­bodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens. 2000; 18: 945-53

26) Liao YH, Wei YM, Cheng LX, et al. Autoanti­bodies against AT1-receptor and alpha1-adorena­gic receptor in patients with hypertension. Hypertens Res. 2002; 25: 641-6

27) Dragun D, Muller DN, Wallukat G, et al. Angio­tensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005; 352: 558-69

28) Yang X, Wang F, Liu H, et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens. 2008; 26: 1629-35

29) Irani RA, Xia Y. The functional role of the rennin-angiotensin system in pregnancy and preeclampsia. Placenta. 2009; 29: 763-71

30) Xia Y, Chenyi C, Kellems RE, et al. Angiotensin receptors, autoimmunity, and preeclampsia. J Immunology. 2007; 179: 3391-5

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp